Nyxoah S.A.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $142.1M
- Price
- $1.42
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.70%
- Volume
- 81.5K
About
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Quick stats
Shares outstanding100.1M
Computed float75.9M
Float / shares75.9%
Cash runway (months)12.1
Key info
SectorHealthcare
IndustryMedical - Specialties
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001857190
Websitehttps://www.nyxoah.com
AI Summary
AI-generated1/50
standardbullishexecutive change
Nyxoah Appoints Liam Kelly as Chief Executive Officer
Nyxoah SA (Nasdaq/Euronext: NYXH) appointed Liam Kelly as Chief Executive Officer effective October 1, 2026, succeeding Olivier Taelman after seven years at the helm.
Kelly was Chairman, President and CEO of Teleflex until January 2026 and currently serves on the board of Enovis Corporation (NYSE: ENOV), bringing more than 25 years of MedTech leadership experience.
The move underscores Nyxoah's shift to a US-focused commercial organization following August 2025 FDA approval and the early-stage launch of its Genio neuromodulation therapy for obstructive sleep apnea.
For Enovis, the news is contextual: its director takes a full-time CEO role elsewhere, which investors may monitor for board-commitment implications.